Effect of surface charge on the size-dependent cellular internalization of liposomes

Sakai‐Kato, Kumiko; Yoshida, Kohki; Izutsu, Ken‐ichi

doi:10.1016/j.chemphyslip.2019.01.004

Cited by 33 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sakai-Kato et al. 162 found that in a certain range (100–200 nm), the TE of lipoplexes was enhanced with the increase of particle size, which was due to the strong electrostatic interaction between CL and plasma membrane. Instead, however, Bruininks et al.…”

Section: Main Textmentioning

confidence: 99%

Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy

Liu

Zhang

Zhu

et al. 2020

Molecular Therapy - Methods & Clinical Development

156

View full text Add to dashboard Cite

Cationic liposomes (CLs) have been regarded as the most promising gene delivery vectors for decades with the advantages of excellent biodegradability, biocompatibility, and high nucleic acid encapsulation efficiency. However, the clinical use of CLs in cancer gene therapy is limited because of many uncertain factors in vivo . Extracellular barriers such as opsonization, rapid clearance by the reticuloendothelial system and poor tumor penetration, and intracellular barriers, including endosomal/lysosomal entrapped network and restricted diffusion to the nucleus, make CLs not the ideal vector for transferring extrinsic genes in the body. However, the obstacles in achieving productive therapeutic effects of nucleic acids can be addressed by tailoring the properties of CLs, which are influenced by lipid compositions and surface modification. This review focuses on the physiological barriers of CLs against cancer gene therapy and the effects of lipid compositions on governing transfection efficiency, and it briefly discusses the impacts of particle size, membrane charge density, and surface modification on the fate of CLs in vivo , which may provide guidance for their preclinical studies.

show abstract

Section: Main Textmentioning

confidence: 99%

Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy

Liu

Zhang

Zhu

et al. 2020

Molecular Therapy - Methods & Clinical Development

156

View full text Add to dashboard Cite

show abstract

“…Liposomes can also improve drug stability, increase drug solubility, and promote biocompatibility [26]. On the other hand, studies have shown that the drug delivery system of solid nanoparticles (in the range of 10–1000 nm) can concentrate 80% of the drug dosage in the liver, enabling the drug to enter the liver cells [27]. Jing Zhu et al found that galangin-liposomes possessed good liver targeting effects [28].…”

Section: Discussionmentioning

confidence: 99%

The Phenylethanol Glycoside Liposome Inhibits PDGF-Induced HSC Activation via Regulation of the FAK/PI3K/Akt Signaling Pathway

Zhang

Zhao

et al. 2019

Molecules

View full text Add to dashboard Cite

Cistanche tubulosa is a traditional Chinese herbal medicine that is widely used to regulate immunity, and phenylethanol glycosides (CPhGs) are among the primary components responsible for this activity. However, the application of CPhGs is negatively affected by their poor absorption and low oral utilization. Targeted drug delivery is an important development direction for pharmaceutics. Previous studies have indicated that CPhGs could block the conduction of the signaling pathways in TGF-β1/smad and inhibit the activation of hepatic stellate cells (HSCs). The aim of this study was to evaluate the anti-hepatic fibrosis effect of CPhG liposomes by inhibiting HSC activation, promoting apoptosis, blocking the cell cycle, suppressing the conduction of signaling pathways in focal adhesion kinase(FAK)/phosphatidylinositol-3-kinase(PI3K)/protein kinase B(Akt), and determining their in vitro hepatoprotective activity. In vitro release studies demonstrated that CPhG liposomes have a sustained release effect compared to drug CPhGs. HSC proliferation was inhibited after treatment with the CPhG liposomes (29.45, 14.72, 7.36 µg/mL), with IC50 values of 42.54 µg/mL in the MTT assay. Different concentrations of the CPhG liposomes could inhibit HSC proliferation, promote apoptosis, and block the cell cycle. The MTT method showed an obvious inhibition of HSC proliferation after CPhG liposome and Recombinant Rat Platelet-derived growth factor-BB(rrPDGF-BB) treatment. The levels of collagen-1, metallopeptidase inhibitor 1 (TIMP-1), α smooth muscle actin (α-SMA), and phosphorylated PI3K/Akt were downregulated, and matrix metalloproteinase-1 (MMP-1) was upregulated, by pretreatment with different concentrations of CPhG liposomes. Moreover, 29.45 μg/mL of CPhG liposomes could decrease the expression of the FAK protein and the phosphorylated PI3K and Akt protein downstream of FAK by overexpression of the FAK gene. This experiment suggests that CPhG liposomes may inhibit the activation of HSCs by inhibiting FAK and then reducing the expression of phosphorylated Akt/PI3K, thereby providing new insights into the application of CPhGs for liver fibrosis.

show abstract

“…Liposomes are spherical vesicle structures comp rised of a phospholipid bilayer shell and aqueous lumen with sizes ranging from a few nanometers to several microns (34,37). These vesicles have been engineered to optimize their immunological role using several approaches including modulation of size and charge (38,39), surface decoration with immune cell recognition epitopes (40,41), and PEGylation to enhance in vivo circulation times (42). An adjuvantedliposomal vaccine formulation AS01 B is marketed by GlaxoSmithKline as a component of Shingles vaccine (Shingrix) (43) and is also in human clinical trials for malaria (44) and HIV (45) vaccines.…”

Section: Liposomesmentioning

confidence: 99%

The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems

Soni

Bobbala

et al. 2020

Pediatr Res

View full text Add to dashboard Cite

Infection is the predominant cause of mortality in early life, and immunization is the most promising biomedical intervention to reduce this burden. However, very young infants fail to respond optimally to most vaccines currently in use, especially neonates. In 2005, Stanley Plotkin proposed that new delivery systems would spur a new revolution in pediatric vaccinology, just as attenuation, inactivation, cell culture of viruses, genetic engineering, and adjuvantation had done in preceding decades. Recent advances in the field of immunoengineering, which is evolving alongside vaccinology, have begun to increasingly influence vaccine formulation design. Historically, the particulate nature of materials used in many vaccine formulations was empiric, often because of the need to stabilize antigens or reduce endotoxin levels. However, present vaccine delivery systems are rationally engineered to mimic the size, shape, and surface chemistry of pathogens, and are therefore often referred to as “pathogen-like particles”. More than a decade from his original assessment, we re-assess Plotkin’s prediction. In addition, we highlight how immunoengineering and advanced delivery systems may be uniquely capable of enhancing vaccine responses in vulnerable populations, such as infants. Impact Immunoengineering and advanced delivery systems are leading to new developments in pediatric vaccinology.Summarizes delivery systems currently in use and development, and prospects for the future.Broad overview of immunoengineering’s impact on vaccinology, catering to Pediatric Clinicians and Immunologists.

show abstract

Effect of surface charge on the size-dependent cellular internalization of liposomes

Cited by 33 publications

References 22 publications

Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy

Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy

The Phenylethanol Glycoside Liposome Inhibits PDGF-Induced HSC Activation via Regulation of the FAK/PI3K/Akt Signaling Pathway

The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems

Contact Info

Product

Resources

About